RU2583876C2 - Иммуноконъюгаты направленного действия - Google Patents

Иммуноконъюгаты направленного действия Download PDF

Info

Publication number
RU2583876C2
RU2583876C2 RU2012110127/10A RU2012110127A RU2583876C2 RU 2583876 C2 RU2583876 C2 RU 2583876C2 RU 2012110127/10 A RU2012110127/10 A RU 2012110127/10A RU 2012110127 A RU2012110127 A RU 2012110127A RU 2583876 C2 RU2583876 C2 RU 2583876C2
Authority
RU
Russia
Prior art keywords
seq
sequence
immunoconjugate
variable region
light chain
Prior art date
Application number
RU2012110127/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012110127A (ru
Inventor
ХОССЕ Ральф
МЁССНЕР Эккехард
СИЛАЧЧИ-МЕЛЬККО Микела
УМАНА Пабло
Original Assignee
Роше Гликарт Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2583876(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Роше Гликарт Аг filed Critical Роше Гликарт Аг
Publication of RU2012110127A publication Critical patent/RU2012110127A/ru
Application granted granted Critical
Publication of RU2583876C2 publication Critical patent/RU2583876C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2012110127/10A 2009-08-17 2010-08-13 Иммуноконъюгаты направленного действия RU2583876C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23458409P 2009-08-17 2009-08-17
US61/234,584 2009-08-17
EP10162410.4 2010-05-10
EP10162410 2010-05-10
PCT/EP2010/061810 WO2011020783A2 (en) 2009-08-17 2010-08-13 Targeted immunoconjugates

Publications (2)

Publication Number Publication Date
RU2012110127A RU2012110127A (ru) 2013-09-27
RU2583876C2 true RU2583876C2 (ru) 2016-05-10

Family

ID=43033282

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012110127/10A RU2583876C2 (ru) 2009-08-17 2010-08-13 Иммуноконъюгаты направленного действия

Country Status (21)

Country Link
US (1) US8945571B2 (enExample)
EP (1) EP2467165B1 (enExample)
JP (1) JP5764127B2 (enExample)
KR (2) KR101588598B1 (enExample)
CN (1) CN102573922B (enExample)
AR (1) AR077879A1 (enExample)
AU (1) AU2010285071A1 (enExample)
CA (1) CA2769619C (enExample)
CO (1) CO6430436A2 (enExample)
CR (1) CR20120042A (enExample)
EC (1) ECSP12011685A (enExample)
ES (1) ES2534085T3 (enExample)
IL (1) IL217844A0 (enExample)
MA (1) MA33717B1 (enExample)
MX (1) MX2012002014A (enExample)
PE (1) PE20120630A1 (enExample)
RU (1) RU2583876C2 (enExample)
SG (1) SG178443A1 (enExample)
TW (1) TW201119672A (enExample)
WO (1) WO2011020783A2 (enExample)
ZA (1) ZA201200767B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2758143C1 (ru) * 2018-02-09 2021-10-26 Филоджен С.П.А. Композиции il-12, нацеленные на edb
US11168139B2 (en) 2016-11-28 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
RU2786730C2 (ru) * 2017-05-24 2022-12-26 Новартис Аг Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
US12030955B2 (en) 2017-11-28 2024-07-09 Chugai Seiyaku Kabushiki Kaisha Polypeptide including antigen-binding domain and carrying section
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
EP2603529A1 (en) * 2010-08-13 2013-06-19 Roche Glycart AG Anti-tenascin-c a2 antibodies and methods of use
CA2806021C (en) * 2010-08-13 2019-05-21 Roche Glycart Ag Anti-fap antibodies and methods of use
AU2015213405B2 (en) * 2010-08-13 2017-08-03 Roche Glycart Ag Anti-FAP antibodies and methods of use
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
CA2849033C (en) * 2011-09-26 2020-05-05 Philogen S.P.A. Immunocytokine combination therapy
ES2694180T3 (es) 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
MY175687A (en) * 2012-08-07 2020-07-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
CA2878626A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US9561275B2 (en) 2012-09-14 2017-02-07 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
BR112016001128A2 (pt) 2013-07-19 2018-01-23 Vib Vzw membros da família il-1 modificados direcionados
SG10202010429YA (en) 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾ｔｎｆファミリーメンバー
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
GB201500875D0 (en) 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
US11319344B2 (en) * 2015-02-13 2022-05-03 Agency For Science, Technology And Research Non-membrane disruptive P53 activating stapled peptides
EP3973980A1 (en) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US10526413B2 (en) * 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US10696722B2 (en) 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
KR20190092371A (ko) * 2016-09-21 2019-08-07 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 섬유아세포 활성화 단백질을 표적화하는 최적화된 합성 컨센서스 면역원성 조성물
ES3007557T3 (en) 2016-10-17 2025-03-20 Pfizer Anti-edb antibodies and antibody-drug conjugates
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017380981B2 (en) * 2016-12-19 2025-01-30 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) * 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CN110505883A (zh) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
KR20200016874A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제를 포함하는 병용 요법
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
AU2018313810B2 (en) 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019271263A1 (en) * 2018-05-16 2020-12-03 Dragonfly Therapeutics, Inc. Protein binding NKG2D, CD16 and a fibroblast activation protein
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN112513276B (zh) * 2018-07-30 2024-03-15 张晋宇 蛋白质异二聚体及其用途
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
EP3847242A4 (en) * 2018-09-07 2022-06-08 NantBio, Inc. TARGETED IL-12 TREATMENTS AND METHODS TO STIMULATE HANK AND NK92MI CELLS
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
WO2020257412A1 (en) 2019-06-19 2020-12-24 Orionis Biosciences, Inc. Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
CN114258400A (zh) 2019-08-15 2022-03-29 詹森生物科技公司 用于改进的单链可变片段的材料和方法
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2021252514B2 (en) * 2020-04-06 2025-06-26 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
AU2021256936A1 (en) 2020-04-15 2022-07-21 F. Hoffmann-La Roche Ag Immunoconjugates
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
IL300534A (en) * 2020-08-11 2023-04-01 Kanaph Therapeutics Inc A fusion protein containing 12-il and an anti-fap antibody, and its use
KR20230117122A (ko) 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4297785A4 (en) 2021-02-26 2025-01-22 New York University COMPOSITIONS AND METHODS USING ANTIBODIES FOR BINDING TO COVALENT PEPTIDE CONJUGATES
WO2022189377A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
IL312005A (en) 2021-10-14 2024-06-01 Hoffmann La Roche New interleukin-7 immunoconjugates
CN118139648A (zh) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 用于治疗癌症的替代的PD1-IL7v免疫缀合物
EP4437006A1 (en) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
JP7690131B2 (ja) * 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
CR20250288A (es) 2023-01-20 2025-08-29 Hoffmann La Roche POLIPÉPTIDOS DE DOMINIO Fc -VARIANTE DE IL2 RECOMBINANTES Y POLITERAPIA CON POLIPÉPTIDOS DE UNIÓN AL ANTÍGENO ANCLADOS A LA MEMBRANA
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039363A2 (en) * 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
ES2590912T3 (es) * 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001075110A2 (en) * 2000-03-30 2001-10-11 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
US8744844B2 (en) * 2007-07-06 2014-06-03 Audience, Inc. System and method for adaptive intelligent noise suppression
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP2187971A2 (en) * 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services A fold-back diabody diphtheria toxin immunotoxin and methods of use
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039363A2 (en) * 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168139B2 (en) 2016-11-28 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
RU2803067C2 (ru) * 2016-11-28 2023-09-06 Чугаи Сейяку Кабусики Кайся Лигандсвязывающая молекула с регулируемой лигандсвязывающей активностью
US11932697B2 (en) 2016-11-28 2024-03-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
RU2827545C2 (ru) * 2016-11-28 2024-09-30 Чугаи Сейяку Кабусики Кайся Полипептид, содержащий антигенсвязывающий домен и транспортирующий сегмент
RU2827545C9 (ru) * 2016-11-28 2024-10-18 Чугаи Сейяку Кабусики Кайся Полипептид, содержащий антигенсвязывающий домен и транспортирующий сегмент
RU2786730C2 (ru) * 2017-05-24 2022-12-26 Новартис Аг Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
US12030955B2 (en) 2017-11-28 2024-07-09 Chugai Seiyaku Kabushiki Kaisha Polypeptide including antigen-binding domain and carrying section
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
RU2854398C1 (ru) * 2017-11-28 2025-12-30 Чугаи Сейяку Кабусики Кайся Лигандсвязывающая молекула с регулируемой лигандсвязывающей активностью
RU2758143C1 (ru) * 2018-02-09 2021-10-26 Филоджен С.П.А. Композиции il-12, нацеленные на edb
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety

Also Published As

Publication number Publication date
JP2013502209A (ja) 2013-01-24
AU2010285071A1 (en) 2012-02-02
ES2534085T3 (es) 2015-04-17
JP5764127B2 (ja) 2015-08-12
ZA201200767B (en) 2014-07-30
KR20150088328A (ko) 2015-07-31
WO2011020783A3 (en) 2011-04-28
MX2012002014A (es) 2012-06-13
CN102573922B (zh) 2015-08-05
TW201119672A (en) 2011-06-16
EP2467165B1 (en) 2015-01-07
HK1169318A1 (zh) 2013-01-25
WO2011020783A2 (en) 2011-02-24
CR20120042A (es) 2012-03-22
US8945571B2 (en) 2015-02-03
RU2012110127A (ru) 2013-09-27
CN102573922A (zh) 2012-07-11
CA2769619A1 (en) 2011-02-24
US20110064751A1 (en) 2011-03-17
MA33717B1 (fr) 2012-11-01
ECSP12011685A (es) 2012-03-30
KR20120053042A (ko) 2012-05-24
IL217844A0 (en) 2012-03-29
CA2769619C (en) 2019-04-30
EP2467165A2 (en) 2012-06-27
KR101588598B1 (ko) 2016-01-29
CO6430436A2 (es) 2012-04-30
PE20120630A1 (es) 2012-05-26
SG178443A1 (en) 2012-04-27
AR077879A1 (es) 2011-09-28

Similar Documents

Publication Publication Date Title
RU2583876C2 (ru) Иммуноконъюгаты направленного действия
JP7633810B2 (ja) 抗ｓｔｅａｐ１抗原結合タンパク質
JP2013502209A5 (enExample)
US10323098B2 (en) Mutant interleukin-2 polypeptides
CN111410691B (zh) 结合至cd38和cd3的双特异性抗体
EP3565838A1 (en) Conditional agonists of immune responses
KR20130118941A (ko) 면역치료법
RU2723940C2 (ru) Биспецифические антигенсвязывающие полипептиды
CA2859444A1 (en) Use of n-hydroxysuccinimide to improve conjugate stability
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
BR112012003739A2 (pt) imunoconjugados, polinucleotídeo, microorganismo transgênico, método para produzir o imunoconjugado, composição e usos do imunoconjugado e da composição
HK1169318B (en) Targeted immunoconjugates
HK1233656A1 (en) Bi-specific antigen-binding polypeptides
HK1233656B (en) Bi-specific antigen-binding polypeptides